This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2005 Apr;42(2 Suppl 1):S10-3.

doi: 10.1053/j.seminhematol.2005.01.002.

Management of anemia associated with myelodysplastic syndrome

E Hellström-Lindberg¹

Affiliations

PMID: 15846579
DOI: 10.1053/j.seminhematol.2005.01.002

Review

Management of anemia associated with myelodysplastic syndrome

E Hellström-Lindberg. Semin Hematol. 2005 Apr.

. 2005 Apr;42(2 Suppl 1):S10-3.

doi: 10.1053/j.seminhematol.2005.01.002.

Author

E Hellström-Lindberg¹

Affiliation

¹ Department of Medicine, Huddinge Hospital, Division of Hematology, Huddinge, Sweden. hellstrom-lindberg@medhs.ki.se

PMID: 15846579
DOI: 10.1053/j.seminhematol.2005.01.002

No abstract available

PubMed Disclaimer

Similar articles

Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML. Thomas ML. Eur J Oncol Nurs. 2007 Apr;11(2):151-8. doi: 10.1016/j.ejon.2006.06.004. Epub 2006 Aug 28. Eur J Oncol Nurs. 2007. PMID: 16935559 Review.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Park S, et al. J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28. J Clin Oncol. 2017. PMID: 28350519
The role of erythropoietin and other growth factors in transfusion medicine.
Klingemann HG, Shepherd JD, Eaves CJ, Eaves AC. Klingemann HG, et al. Transfus Med Rev. 1991 Jan;5(1):33-47. doi: 10.1016/s0887-7963(91)70191-0. Transfus Med Rev. 1991. PMID: 1802275 Review. No abstract available.
The role of hematopoietic growth factors in the treatment of neoplastic diseases.
St Onge J, Jacobson RJ. St Onge J, et al. Semin Hematol. 1992 Jul;29(3 Suppl 2):53-63. Semin Hematol. 1992. PMID: 1380737 Review. No abstract available.
[Anemia in the elderly patient. Is it a myelodysplastic syndrome?].
[No authors listed] [No authors listed] MMW Fortschr Med. 2012 Feb 23;154(3):26. MMW Fortschr Med. 2012. PMID: 22458163 German. No abstract available.

See all similar articles

Cited by

Oxidative Stress in β-Thalassemia.
Fibach E, Dana M. Fibach E, et al. Mol Diagn Ther. 2019 Apr;23(2):245-261. doi: 10.1007/s40291-018-0373-5. Mol Diagn Ther. 2019. PMID: 30484264 Review.
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.
Singhal D, Kutyna MM, Chhetri R, Wee LYA, Hague S, Nath L, Nath SV, Sinha R, Wickham N, Lewis ID, Ross DM, Bardy PG, To LB, Reynolds J, Wood EM, Roxby DJ, Hiwase DK. Singhal D, et al. Haematologica. 2017 Dec;102(12):2021-2029. doi: 10.3324/haematol.2017.175752. Epub 2017 Oct 5. Haematologica. 2017. PMID: 28983058 Free PMC article.
Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.
Mukherjee S, Brown-Bickerstaff C, Falkenstein A, Makinde AY, Bland E, Laney J, Garretson M, Huggar D, McBride A. Mukherjee S, et al. Hemasphere. 2024 Jan 30;8(1):e38. doi: 10.1002/hem3.38. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434524 Free PMC article. No abstract available.
Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Shenoy N, et al. Blood. 2014 Aug 7;124(6):873-81. doi: 10.1182/blood-2014-03-563221. Epub 2014 Jun 12. Blood. 2014. PMID: 24923296 Free PMC article. Review.
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.
Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan AM. Awidi A, et al. JCO Glob Oncol. 2024 Feb;10:e2300281. doi: 10.1200/GO.23.00281. JCO Glob Oncol. 2024. PMID: 38422464 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information